LASER-ASSISTED-INDOCYANINE-GREEN-ANGIOGRAPHY VERSUS CONVENTIONAL ASSESSMENT TO PREDICT OR LOCATE NECROTIC AREAS ON MASTECTOMY FLAPS: A PROSPECTIVE CLINICAL TRIAL

MASTEKTOMİ FLEBİ NEKROZUNU TAHMİN YA DA LOKALİZE EDEBİLEN LAZER YARDIMLI İNDOSİYANİN YEŞİLİ ANJİOGRAFİNİN KONVANSİYONEL YÖNTEMLE KIYASLANMASI: PROSPEKTİF KLİNİK ÇALIŞMA

Fatih Levent BALCI1, Cihan URAS2

1Medipol University Mega Hospital, Department of General Surgery, Istanbul, Turkey
2Acibadem University, Department of General Surgery, Istanbul, Turkey

ORCID IDs of the authors: F.L.B. 0000-0001-8460-9355; C.U. 0000-0002-6838-2311


ABSTRACT

Objective: The aim of this study was to determine whether laser-assisted-indocyanine-green-angiography (LA-ICGA) could accurately predict flap necrosis in comparison to conventional clinical assessment and visually identify its location during immediate reconstruction following a nipple-sparing mastectomy (NSM).

Methods: Twenty-one patients with breast cancer were prospectively enrolled to undergo NSM with immediate implant reconstruction. In 19 cases LA-ICGA numbers were used to show the level of laser absorption of hypo-perfused areas on the mastectomy flaps. Those numbers were compared to conventional assessment to assess the predictive value of LA-ICGA.

Results: Of the 19 mastectomy flaps, 3 (15.8%) examples of partial skin flap necrosis with an LA-ICGA value of ≤7 was observed. The sensitivity, specificity, false-positive rate, and accuracy of LA-ICGA were 43%, 100%, 57%, and 79%, respectively. Patients with an LA-ICGA value of ≤7 were found more likely to develop mastectomy flap necrosis, whereas patients aged >60 or, a history of smoking, a BMI >30, or intraoperative use of tumescence solution containing epinephrine were more likely to have an LA-ICGA score ≤7 which is not clinically reliable in predicting necrosis.

Conclusion: Our results indicate that a low LA-ICGA score ≤7 is the only significant factor in predicting mastectomy flap necrosis. LA-ICGA could accurately show the location of necrosis.

Keywords: SPY, intraoperative angiography, nipple-sparing mastectomy, breast Cancer

ÖZET

Amaç: Bu çalışmada meme-başı koruyucu mastektomi (MBKM) fleplerindeki nekroz yada nekroz lokalizasyonunu, lazer yardımcılı indosiyanın yeşilli angiografisinin (LYIYA) tahmin edip edemeyeceğini konvansiyonel gözlem ile kıyaslama yapmakta idi.

Yöntem: Meme kanseri nedeniyle 21 hastaya MBKM ve eşzamalı silikon implant rekonstrüksiyon yapıldı. Ondokuz hastada flep üzerindeki hipoperfuze alanların lazer absorpsiyon derecesini ve LYIYA sayısını kullanarak yerindeki nekroz lokalizasyonunu ve sınırlarını kıyaslama çalışması yapılmıştır. 

Bulgular: Bu 19 mastektomi flebinin 3’ünde (15.8%) parsiyel cilt nekrozu saptanmış, LYIYA sayisi ≤7 olarak saptanmıştır. LYIYA’nın duyarlılığı, özgüllüğü, falsen pozitif ve doğruluğu sırasıyla 43%, 100%, 57% ve 79% olarak bulunmuştur. LYIYA ≤7 olan hastalarda daha çok nekroz saptanmış, 60 yaş üstü, sigara öyküsü, BMI >30 veya intraoperatif tumescence solusyona alanlarda LYIYA ≤7 yanıltıcı bulgusal bulunmuş, nekroz tahmininde yanılış yapan örneklerdir.

Sonuç: LYIYA sayısının ≤7 bulgusu, mastektomi flep nekrozunu tahmin edebilme becerisini göstermektedir. LYIYA ≤7 olan hastalarda daha çok nekroz saptanmış, 60 yaş üstü, sigara öyküsü, BMI >30 veya intraoperatif tumescence solusyona alanlarda LYIYA ≤7 yanıltıcı bulunmuş, nekroz tahmininde yanılış yapan örneklerdir.

Anahtar Kelimeler: SPY, lazer yardımcı indosiyanın yeşilli angiografi, meme başı koruyucu mastektomi, meme kanseri

Corresponding author/İletişim kurulacak yazar: fatihleventbalci@gmail.com
Submitted/Başvuru: 22.05.2019 • Accepted/Kabul: 12.07.2019 • Published Online/Online Yayın: 26.08.2019
©Telif Hakki 2019 J Ist Faculty Med - Makale metnine jmed.istanbul.edu.tr web sayfasından ulaşılabilir. ©Copyright 2019 by J Ist Faculty Med - Available online at jmed.istanbul.edu.tr
INTRODUCTION

Immediate reconstructive procedures have been made more feasible through surgical approaches that preserve the natural skin envelope, including skin-sparing and the nipple-sparing mastectomy. Critical issues in immediate reconstructive procedures include coverage of the implant, the use of an appropriate tissue expander or silicone, and the quality and viability of tissue flaps. The quality and viability of mastectomy flaps is a central challenge in reconstructive surgery. A leading cause of early complications following reconstructive procedures is insufficient perfusion in the tissue flaps (1-4). For this reason, surgeons have evaluated and employed many methods to assess tissue perfusion in the intraoperative setting. An ideal technique would allow for the accurate identification of perforating vessels and their perfusion zones, assessment of tissue perfusion, and identification of tissue at risk for necrosis. Clinical judgment is the most widely used method for evaluating blood supply and tissue viability (5). However, some evidence suggests that clinical assessment alone is not entirely reliable for assessing tissue perfusion (6,7).

To reduce the occurrence of mastectomy necrosis, intraoperative laser-assisted indocyanine green angiography, has been increasingly advertised as a useful preventative measure (8,9). Laser-assisted indocyanine green angiography (LA-ICGA) provides live imaging of fluorescent indocyanine green injected into the patient’s bloodstream, which then permeates the patient’s tissue. When such a patient’s mastectomy flap is viewed under the scanner, well-perfused tissue appears fluorescent and ischemic tissue appears dark. This technology allows the immediate assessment of the viability of the mastectomy flap and facilitates intraoperative decision-making concerning how much tissue to excise so that no ischemic tissue is left behind that will result in mastectomy necrosis (10).

The fluorescence agent ICG has a short half-life, binds strongly to plasma proteins, and has an excellent safety profile, allowing for rapid clearance from tissues and the performance of repeat evaluations during the same surgical procedure (11). Recent work suggests that the LA-ICGA also provides greater accuracy compared to fluorescence in clinical judgment for the prediction of mastectomy flap necrosis (8). This study aims to determine whether LA-ICGA can accurately predict skin flap necrosis and visually identifies its location during nipple or skin-sparing mastectomies with immediate reconstruction at our institution.

METHODS

Twenty-one consecutive patients diagnosed with invasive breast cancer who underwent nipple-sparing mastectomy with immediate silicone gel implant reconstruction were prospectively enrolled in the study. Those skin flaps or edges, which were predicted to be ischemic by LA-ICGA, but physically assessed as normal by the surgeon, were not excised intraoperatively to assess the accuracy of SPY-Q numbers (represent quantitative laser absorption of hypoperfused areas) on flap necrosis. The SPY-Q numbers equal to or fewer than seven were considered as predictors for tissue necrosis (12). Exclusion criteria included skin-reducing NSMs, delayed reconstruction, iodine allergy or intolerance to ICG dye. The study was approved by the Acibadem University Ethics Committee (#2016-11/12), and informed consent was obtained from all the enrolled patients.

Surgical technique

Since periareolar or medial/lateral extension incisions result in a slightly higher rate of nipple necrosis after NSMs followed by immediate reconstruction, lateral incisions which start at least 2 cm away from the nipple was the preferred incision made by the breast surgeon in the majority of our cases. Inframammary fold incisions (which are chosen to achieve more cosmetic satisfaction), were used less frequently. Permanent silicone implants were used immediately for the reconstruction with a created sub-muscular pocket created by a plastic surgeon. In order to cover and support the inferior aspect of the breast pocket, an acellular dermal matrix was used when needed.

Laser-assisted Indocyanine green (ICG) angiography protocol

After completion of the nipple-sparing mastectomy by a breast surgeon, each patient underwent visualization of mastectomy skin flaps using the SPY Elite System (Life Cell Corp., Branchburg, NJ, USA). 0.02 mg/kg of ICG dye was administered intravenously followed by 10cc of normal saline. Perfusion scores were recorded on LA-ICGA for a total of 120 sec after visualization of fluorescence in mastectomy skin flaps. SPY-Q software numbers were chosen, which represents absolute perfusion levels.

Study design

One surgeon examined the physical appearance in regards to the vitality of the localized area of the skin and nipple for two weeks at four weeks intervals. The necrotic areas were recorded and photographed to compare them with the images obtained using LA-ICGA. The results achieved from the comparison of the conventional assessment versus LA-ICGA were used to determine whether the LA-ICGA is statistically significant to use clinically for the prediction of flap necrosis.

Statistical analysis

SPSS 16 (Chicago, USA) was used for statistical analyses. Descriptive analyses were performed, and associations
between categorical variables were determined by Pearson’s Chi-square test or Fisher’s exact test as appropriate. Sensitivity, specificity, positive predictive value, and negative predictive value were assessed to evaluate the feasibility of LA-ICGA in predicting flap necrosis. P values <0.05 were considered statistically significant; all tests were two-sided.

RESULTS

Between January 2016 and August 2016, 21 consecutive consenting patients diagnosed with breast cancer were enrolled to undergo LA-ICGA in addition to NSM. Four patients who underwent further circumareolar excision for skin-reducing following LA-ICGA procedures were excluded from the analyses. Of the remaining 17 patients, two patients underwent bilateral NSM to reduce the contralateral side. Therefore, a total of 19 mastectomy specimens were evaluated in the study. The median age was 47 (36-68, range). All patients were diagnosed with a clinical-stage I-III invasive cancer. Of those, two patients had undergone neoadjuvant chemotherapy before surgery, whereas the remaining patients had undergone surgery before adjuvant chemotherapy and/or radiotherapy.

The median score was 9 (1-57). Of the 19 mastectomy flaps, 3 (15.8%) cases of partial skin flap necrosis were observed in the postoperative four weeks (Images 1 and 2). Of those, one patient underwent nipple excision, and 2 cases underwent partial debridement. None of the patients with an LA-ICGA score >7 developed postoperative necrosis, whereas four patients similarly did not have postoperative flap necrosis, even though ≤7 SPY scores were preoperatively estimated. The false-positive rate was, therefore estimated to be 57.1%.

Furthermore, the sensitivity, specificity, and accuracy of LA-ICGA in predicting flap necrosis were 43%, 100%, and 79%, respectively. Patients with a low LA-ICGA score <7 were more likely to develop mastectomy flap necrosis in the fourth postoperative week, whereas other factors such as smoking, diabetes mellitus or neoadjuvant chemotherapy were not found statistically significant (Table 1). Nevertheless, patients aged >60, with a smoking history, a BMI>30, or intraoperative use of tumescence solution containing epinephrine were more likely to have an LA-ICGA score ≤7 which did not predict postoperative flap necrosis (Table 2). LA-ICGA was also able to identify the edges or location of necrotic areas in true positive cases (Figure 1 and 2).

DISCUSSION

Mastectomy skin flap necrosis is one of several frequent complications associated with increased morbidity in breast reconstruction. The significance of accurately predicting mastectomy skin flap viability cannot be emphasized enough, because such predictions will reduce postoperative morbidity. Although preservation of breast skin contributes to the aesthetic outcome, the presence of necrotic skin flaps contributes to delayed healing, complications, and poor outcome. Necrosis is even more critical when prosthetic implants are being used for re-

<table>
<thead>
<tr>
<th>Table 1: Factors associated with postoperative flap necrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Necrosis (+)</td>
</tr>
<tr>
<td>SPY score ≤ 7</td>
</tr>
<tr>
<td>SPY score &gt;7</td>
</tr>
<tr>
<td>Age ≥ 60</td>
</tr>
<tr>
<td>Age &lt; 60</td>
</tr>
<tr>
<td>Body mass index ≥ 30</td>
</tr>
<tr>
<td>Body mass index &lt;30</td>
</tr>
<tr>
<td>Smoking history (+)</td>
</tr>
<tr>
<td>Smoking history (-)</td>
</tr>
<tr>
<td>Peroperative use of tumescence solution containing epinephrine (+)</td>
</tr>
<tr>
<td>Peroperative use of tumescence solution containing epinephrine (-)</td>
</tr>
<tr>
<td>Past history of diabetes mellitus (+)</td>
</tr>
<tr>
<td>Past history of diabetes mellitus (-)</td>
</tr>
<tr>
<td>Past history of autoimmune disease including vasculitis (+)</td>
</tr>
<tr>
<td>Past history of autoimmune disease including vasculitis (-)</td>
</tr>
<tr>
<td>Neoadjuvant chemotherapy (+)</td>
</tr>
</tbody>
</table>
ICG angiography for mastectomy flap necrosis
İstanbul Tıp Fakültesi Dergisi • J Ist Faculty Med 2019;82(4):193-8

construction. Although the safest option is often to resect mastectomy skin, this often removes skin that would likely have survived. We had quantified perfusion scores with the current LA-ICGA and assessed whether SPY-Q software does indeed correlate with the areas, which would have necrosis clinically.

Currently, the standard approach to examine mastectomy flap viability is via clinician assessment intra-operatively. Before closure, the surgeon must assess tissue viability and excise the skin based on the likelihood of necrosis in the postoperative period. With this clinically guided approach, the literature reports mastectomy skin flap necrosis rates of approximately 10-15% (13,14). In the current study, a 15.8% rate of necrosis was observed, which is consistent with the literature. The high rate of flap necrosis after nipple or skin-sparing mastectomies highlights the limitation of current clinical assessment methods used for predicting flap necrosis.

Recently, SPY angiography has been developed as a new tool to evaluate skin perfusion in real-time. The device was designed to assess the patency of bypass anastomoses in cardiac surgery (15,16) as well as to evaluate free tissue transfers or microsurgical perforator anastomoses (17,18). A few studies have been published to assess the ability of LA-ICGA to predict flap necrosis in mastectomies. Komorowska-Timek and Gurtner in a case series of 24 breasts showed that incorporating SPY values into

Table 2: Factors associated with false positivity in the study patients who have <7 SPY-Q score who did not develop postoperative necrosis.

<table>
<thead>
<tr>
<th>Factor</th>
<th>SPY score ≤7</th>
<th>SPY score &gt; 7</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt; 60 vs &lt;60</td>
<td>66.7% (2/3)</td>
<td>12.5% (2/16)</td>
<td>0.097</td>
</tr>
<tr>
<td>Body mass index (BMI) &gt; 30 vs &lt;30</td>
<td>100% (2/2)</td>
<td>11.8% (2/17)</td>
<td>0.035</td>
</tr>
<tr>
<td>Age &gt; 60 or BMI &gt; 30 vs other BMI &gt; 30, and smoking intraoperative use of tumesence solution containing epinephrine (+) vs (-)</td>
<td>75% (3/4)</td>
<td>6.7% (1/15)</td>
<td>0.016</td>
</tr>
<tr>
<td>Smoking history (+) vs (-)</td>
<td>50% (3/6)</td>
<td>7.7% (1/13)</td>
<td>0.071</td>
</tr>
<tr>
<td>Intraoperative use of tumescence solution containing epinephrine (+) vs (-)</td>
<td>100% (1/1)</td>
<td>16.7% (3/18)</td>
<td>0.211</td>
</tr>
<tr>
<td>BMI &gt; 30, and smoking or intraoperative use of tumesence solution containing epinephrine vs other BMI &gt; 30, and smoking or intraoperative use of tumesence solution containing epinephrine vs other</td>
<td>75% (3/4)</td>
<td>6.7% (1/15)</td>
<td>0.016</td>
</tr>
<tr>
<td>Age &gt; 60, or BMI &gt; 30, or smoking or peroperative use of tumesence solution containing epinephrine vs other</td>
<td>50% (1/2)</td>
<td>17.6% (3/17)</td>
<td>0.386</td>
</tr>
<tr>
<td>Past history of diabetes mellitus (+) vs (-)</td>
<td>50% (1/2)</td>
<td>17.6% (3/17)</td>
<td>0.386</td>
</tr>
<tr>
<td>Past history of autoimmune disease including vasculitis (+) vs (-)</td>
<td>50% (1/2)</td>
<td>17.6% (3/17)</td>
<td>0.386</td>
</tr>
<tr>
<td>Neoadjuvant chemotherapy (+) vs (-)</td>
<td>0% (0/3)</td>
<td>26.7% (4/15)</td>
<td>0.999</td>
</tr>
<tr>
<td>Bra size: &gt;85 vs &lt;85</td>
<td>26.7% (4/15)</td>
<td>0% (0/4)</td>
<td>0.530</td>
</tr>
<tr>
<td>Mastectomy specimen weight &gt;400 gr vs &lt;400 gr</td>
<td>30% (3/10)</td>
<td>16.7% (1/6)</td>
<td>0.999</td>
</tr>
<tr>
<td>Implant size &gt;400 cc vs &lt;400</td>
<td>40% (2/5)</td>
<td>14.3 (2/14)</td>
<td>0.999</td>
</tr>
</tbody>
</table>

Figure 1 and 2: Flap necrosis predicted and localized by SPY-Q numbers ≤7 in a case who underwent immediate reconstruction following NSM.
operational decision-making was associated with a decrease in the rate of necrosis from 15% to 4% (1). Furthermore, Jones et al. used LA-ICGA to inform clinical decisions in 64 cases and found that in five cases where LA-ICGA assessment was ignored, four developed necrosis with the last developing blistering in the SPY-predicted distribution (19). These studies did not allow for assessing to what degree LA-ICGA predictions differed from clinical judgment, and whether LA-ICGA over predicted ischemia and also led to the excision of healthy skin not destined for necrosis.

To answer these questions, Newman et al. and Phillips et al. conducted studies where intra-operative excisions were based exclusively on clinician judgment. Newman et al. correlated low LA-ICGA perfusion values to skin necrosis in 20 breasts (20). Phillips et al., in a prospective study of 51 tissue expander reconstructions, attempted to quantify the areas predictive of necrosis to provide some framework for interpreting LA-ICGA perfusion values (8). The study, however, used an outdated version of LA-ICGA, which determined perfusion values based on a different scaling system, and has since been replaced by SPY Elite. Recently, Munabi et al. used LA-ICGA prospectively to assess the correlation between the LA-ICGA values and skin flap necrosis following both implant-based and autologous breast reconstruction, and assess how those values were affected by certain patients factors (12). They found that by considering an LA-ICGA value of 7 as an indicator of necrosis, the sensitivity and specificity of LA-ICGA were maximized to 88% and 83%, respectively. If the cut-off value for necrosis was increased to 13, 100% sensitivity of the device was obtained; however, specificity decreased to 72%. Of all patient factors considered, only temperature and tissue expander volume were found to be statistically significant. All patient temperatures recorded, however, were within reasonable limits of body temperature.

Concerning tissue expander volume, Munabi et al. found that breasts that developed necrosis were statistically more likely to have received a smaller intra-operative fill volume (12). Other researchers have attempted to define threshold values, using the SPY-Q software, which enable reliable prediction of mastectomy skin flap perfusion and necrosis (8,21). Moyer et al. utilized the LA-ICGA perfusion score where the fluorescence was recorded relative to the surrounding well-perfused tissues designated as “100% fluorescent” (21). They showed that a score of less than 33% has a positive predictive value of 88% for necrosis and a negative predictive value of 16% for survival. However, this scoring system was prone to inter-observer variability.

In contrast, Phillips et al. and Munabi et al. employed an absolute measurement of tissue fluorescence to derive sensitivity and specificity of ICG (8,12). In our study, LA-ICGA number 7 was used as a cut-off level, and it was discovered that the LA-ICGA had a high specificity (100%) but low sensitivity (43%) with an accuracy rate of 79%, which is acceptable. Since we preferred to use a silicone implant rather than a tissue expander, we could not compare the fill-volume used in tissue expanders. Body temperatures in our cases were in reasonable limits and were found to be statistically insignificant.

Demographic factors affecting the LA-ICGA efficiency are variable, and there is little data regarding whether the cost-effectiveness LA-ICGA . Munabi et al. documented that sensitivity and specificity can be confounded in smokers and the presence of epinephrine-containing tumescent solution (12). Current evidence indicates that using ICG-based angiography to guide the excision of the hypo-perfused mastectomy skin flap in the operating room results in a significant reduction in necrosis (1,22). Furthermore, in comparison to the historical control, Duggal et al. reported a reduction in the severity of the skin flap necrosis (25% vs. 44.1%) and also the rate of re-operation (6% vs. 14%). These findings translate to a cost saving of USD 614 per patient. However, given the high cost of leasing or purchasing an ICG detector device currently, Kanuri et al. showed that indiscriminate use of ICG in all breast reconstructions is more expensive than the cost related to flap complications by 65% (10). They recommend that reserving the use of FA in high-risk patients—smokers, body mass index (BMI) of greater than 30 kg/m², and mastectomy weight of greater than 800 g—leads to significant cost-savings. In our study, it was discovered that patients aged>60; patients with a history of smoking; patients with a BMI >30, or patients with intra-operative use of tumescent solution containing epinephrine were more likely to have a SPY-Q score ≤7 which is not clinically reliable to predict flap necrosis.

In conclusion, SPY-Q numbers of LA-ICGA could be used to predict and locate the necrotic areas in patients undergoing reconstruction following NSM. The LA-ICGA assessment is a better predictor for necrosis than conventional assessment. We may be able to decrease the rate of postoperative flap necrosis by per-operatively debriding the area that demonstrates lower LA-ICGA numbers. LA-ICGA could change operational decision-making by predicting partial necrotic areas, which avoids undergoing subsequent excision. There is a need to investigate the accuracy and reliability of ICG angiography in a more extensive series of autologous reconstructions. Further prospective clinical trials, which compare clinical assessment versus SPY-Q numbers, are needed.

Ethics Committee Approval: Ethics committee approval was received for this study from the Acıbadem University Ethics Committee.
Informed Consent: Written consent was obtained from the participants.

Peer Review: Externally peer-reviewed.


Conflict of Interest: Authors declared no conflict of interest.

Financial Disclosure: Authors declared no financial support.

REFERENCES


